Good Quality Agreements Support Compliance with CGMP
Drug manufacturers can improve use of quality agreements in contract manufacturing.
FDA finalized its guidance on contract manufacturing, Contract Manufacturing Arrangements for Drugs: Quality Agreements, in November 2016 (1). This document explains how parties that engaged in contract manufacturing can use quality agreements to delineate their roles and ultimately ensure compliance with current good manufacturing practice (CGMP).
In the months since FDA finalized this guidance, how has industry responded? Are manufacturers that establish contracts for specific manufacturing activities using quality agreements effectively? The answer is mixed; yes, many are, but there is room for improvement. In this article, the authors cover the scope and legal underpinnings of the guidance, as well as what FDA investigators may consider regarding a quality agreement during an inspection. The article also provides some examples of issues related to quality agreements that FDA has called out in warning letters since the guidance was finalized.
Read this article in BioPharm International'sOutsourcing Resources 2018 eBook.
View other articles in BioPharm International's Outsourcing Resources 2018 eBook.
Article Details
BioPharm Internationalâ¨
eBook:
Outsourcing Resources 2018
Vol. 31â¨
March 2018â¨
Pages: 16–21
Citation
When referring to this article, please cite it as P. Katz et al., "Good Quality Agreements Support Compliance with CGMP,"
BioPharm International Outsourcing Resources eBook
(March 2018).
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
